New cocktail of drugs shows promise for tough pancreatic cancer
NCT ID NCT06951997
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of five drugs (iparomlimab, tuvonralimab, chidamide, nab-paclitaxel, and gemcitabine) as a first treatment for people with metastatic pancreatic cancer. The study aims to see if this mix can shrink tumors and improve survival. It will enroll 33 participants and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iparomlimab, tuvonralimab, chidamide, albumin-bound paclitaxel, gemcitabine
- What this could lead to
- If successful, this could lead to a new first-line treatment option for metastatic pancreatic cancer, potentially improving response rates and survival.
- What could go wrong
- This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. The drug combination may cause significant side effects and may not prove more effective than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can three common drugs boost chemotherapy against pancreatic cancer?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Smart drug delivers chemo directly to pancreatic cancer cells
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia